MPs push for assisted dying to be expanded to people with a year left to live
MPs and campaigners say that people suffering from Motor Neurone Disease or Parkinson’s should have greater access to an ...
Business Insider10d
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase 1 ...
Stocktwits on MSN10d
Alterity Therapeutics Stock Doubles Premarket On Positive MSA Trial Results: Retail Excitement Soars
Shares of Alterity Therapeutics soared 108% premarket Thursday, surging toward levels last seen in September 2022, with trading volume nearly 75 times the daily average. The clinical-stage biotech ...
BioWorld11d
Alterity’s ATH-434 looks to be disease modifying in multiple system atrophy
Alterity Therapeutics Ltd. reported positive top-line phase II results for lead candidate ATH-434 for treating multiple ...
Stockhead on MSN11d
Health Check: Alterity angles for fast-track FDA approval after positive trial results tackling Parkinson’s-like disorder
for fast-track approval of its treatment for multiple system atrophy (MSA). Alterity shares soared up to 112% this morning ...
Alterity surges after mid-stage trial data for lead asset
Alterity Therapeutics (NASDAQ:ATHA) announced Thursday that its lead candidate, ATH434, slowed clinical progression with a ...
What's Going On With Alterity Therapeutics Shares Thursday?
Alterity Therapeutics shares are moving higher on Thursday after the company reported positive topline results from its Phase 2 clinical trial of ATH434 in early-stage multiple system atrophy.
Alterity Therapeutics price target raised to $12 from $8 at Maxim
Maxim analyst Jason McCarthy raised the firm’s price target on Alterity Therapeutics (ATHE) to $12 from $8 and keeps a Buy rating on the shares ...
Nasdaq10d
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase ...